Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MIST
MIST
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MIST News
CARDAMYST Nasal Spray Now Available at Retail Pharmacies
Jan 26 2026
Newsfilter
Milestone Pharmaceuticals (MIST) Receives EMA Review for Etripamil Nasal Spray
Jan 07 2026
NASDAQ.COM
Aptar Launches CARDAMYST Nasal Spray to Address Needs of 2 Million PSVT Patients
Dec 17 2025
Businesswire
Aptar Launches CARDAMYST Nasal Spray for PSVT Treatment
Dec 17 2025
Newsfilter
MIST Achieves Landmark Approval: FDA Greenlights First Self-Administered Nasal Spray for PSVT
Dec 13 2025
NASDAQ.COM
FDA Grants Approval for Milestone Pharma's CARDAMYST, the First Self-Administered Therapy for PSVT
Dec 13 2025
NASDAQ.COM
Milestone Pharmaceuticals Receives FDA Approval for CARDAMYST to Treat PSVT
Dec 13 2025
Globenewswire
Milestone Pharmaceuticals Receives FDA Approval for CARDAMYST, Benefiting Over 2 Million PSVT Patients
Dec 13 2025
Newsfilter
Milestone Pharma Awaits FDA Decision on CARDAMYST, Stock Under Scrutiny
Dec 05 2025
NASDAQ.COM
Milestone Pharmaceuticals Grants 30,000 Equity Awards to Attract New Employees
Dec 02 2025
Globenewswire
Milestone Pharmaceuticals Grants 30,000 Options to Attract New Employees
Dec 02 2025
Newsfilter
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Milestone® Pharmaceuticals to Showcase Etripamil Data at the 2025 American Heart Association Scientific Sessions
Oct 09 2025
Newsfilter
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Aug 12 2025
Newsfilter
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Jul 11 2025
Benzinga
Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development
Jul 11 2025
NASDAQ.COM
Show More News
